Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Evaluation of Liquid Yeast-Derived Sucrase Enzyme Replacement in Patients With Sucrase-Isomaltase Deficiency
Mark Rosenberg, M.D
Many patients open up more virtually than they do in clinical settings
MARC1 NN6581 : An siRNA targeting MARC1, intended for subcutaneous injection therapy once a month
When glutathione pathways are disrupted, patients experience a cascade of downstream effects, from mitochondrial damage and severe post-exertional malaise (PEM) to impaired liver detoxification and histamine intolerance
Arch Intern Med 1998
US$ 27.98
US$ 28.54
US$ 23.03
-1775582746855.png&w=384&q=75)
US$ 23.80
US$ 26.92
